利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

141 条记录 (耗时 0.026 秒)

    Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
    41.
    发明授权
    Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines 失效
    百日咳毒素突变体，能够产生这种突变体的博德氏菌菌株及其在开发抗百日咳疫苗中的应用

    公开(公告)号：US07427404B1

    公开(公告)日：2008-09-23

    申请号：US08261691

    申请日：1994-06-17

    申请人： Mariagrazia Pizza ,  Antonello Covacci ,  Rino Rappuoli

    发明人： Mariagrazia Pizza ,  Antonello Covacci ,  Rino Rappuoli

    IPC分类号： A61K39/10 ,  C07K14/235

    CPC分类号： C07K14/235 ,  A61K39/00 ,  A61K39/099

    摘要： New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly 44, Thr53 and Gly80 or subunit's 1 aminoacid sequence is deleted and substituted by a different aminoacid residue selected in the group of natural aminoacids; Bordetella strains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described.The Bordetella strains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines.(FIG. 1)

    摘要翻译： 新百日咳毒素（PT）突变体被描述为具有免疫活性且具有降低或没有毒性，其特征在于至少一种氨基酸残基Glu129，Asp11，Trp26，Arg9，Phe50，Asp1，Arg13，Tyr130，Gly86，Ile88，Tyr89 ，Tyr8，Gly 44，Thr53和Gly80或亚基的1个氨基酸序列缺失并被天然氨基酸组中选择的不同氨基酸残基取代; 还描述了能够提供和分泌所述PT突变体的Bordetella菌株及其获得方法和方法。 由它们生产的博德氏菌属菌株和PT突变体特别适用于制备有效的细胞和无细胞的抗百日咳疫苗。 （）

    DNA sequences for immunologically active peptides of pertussis toxin
    45.
    发明授权
    DNA sequences for immunologically active peptides of pertussis toxin 失效
    百日咳毒素免疫活性肽的DNA序列

    公开(公告)号：US5889172A

    公开(公告)日：1999-03-30

    申请号：US479626

    申请日：1995-06-07

    申请人： Mariagrazia Pizza ,  Antonella Bartoloni ,  Rino Rappuoli

    发明人： Mariagrazia Pizza ,  Antonella Bartoloni ,  Rino Rappuoli

    IPC分类号： A61K39/00 ,  C07K14/235 ,  C12N15/31

    CPC分类号： C07K14/235 ,  A61K39/00 ,  Y10S424/832

    摘要： Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.

    摘要翻译： 无毒性或降低毒性的免疫活性多肽可用于制备抗百日咳疫苗。 用于制备所述多肽的方法，其包括用合适培养基培养用包含编码所述多肽的至少一种的基因的杂交质粒转化的微生物，并从所述细胞或培养基中回收所需的多肽。

    85kDa neisserial antigen
    46.
    发明授权
    85kDa neisserial antigen 失效
    85kDa neisserial抗原

    公开(公告)号：US07700119B2

    公开(公告)日：2010-04-20

    申请号：US11264676

    申请日：2005-11-01

    申请人： Marzia Monica Giuliani ,  Mariagrazia Pizza ,  Rino Rappuoli ,  Johan Holst

    发明人： Marzia Monica Giuliani ,  Mariagrazia Pizza ,  Rino Rappuoli ,  Johan Holst

    IPC分类号： A61K39/095 ,  C07H21/04 ,  C12P21/04 ,  C07K14/00

    CPC分类号： C07K14/22 ,  A61K39/00 ,  Y02A50/466

    摘要： An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.

    摘要翻译： 来自脑膜炎奈瑟氏球菌和淋病奈瑟氏球菌的85kDa抗原已被克隆，测序和表达。 该抗原对于脑膜炎奈瑟氏球菌的不同菌株，血清型和血清型以及淋病奈瑟氏球菌，多糖和内酰胺酶是常见的。 脑膜炎奈瑟氏球菌（血清群A和B）和淋病奈瑟氏球菌的蛋白质序列高度同源。

    Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
    47.
    发明授权
    Pertussis toxin mutants, Bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines 失效
    百日咳毒素突变体，能够产生这种突变体的博德氏菌菌株及其在开发抗百日咳疫苗中的应用

    公开(公告)号：US07666436B1

    公开(公告)日：2010-02-23

    申请号：US08431673

    申请日：1995-05-02

    申请人： Mariagrazia Pizza ,  Antonello Covacci ,  Rino Rappuoli ,  Luciano Nencioni

    发明人： Mariagrazia Pizza ,  Antonello Covacci ,  Rino Rappuoli ,  Luciano Nencioni

    IPC分类号： A61K39/10 ,  C07K14/235 ,  C07H21/04

    CPC分类号： C07K14/235 ,  A61K39/00 ,  A61K39/099

    摘要： New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the amino acid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly44, Thr53 and Gly80 of subunit S1 amino acid sequence is deleted and substituted by a different amino acid residue selected in the group of natural amino acids; Bordetella strains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described. The Bordetella strains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines.

    摘要翻译： 新百日咳毒素（PT）突变体被描述为具有免疫活性且具有降低或无毒性的特征，其特征在于至少一个氨基酸残基Glu129，Asp11，Trp26，Arg9，Phe50，Asp1，Arg13，Tyr130，Gly86，Ile88， 亚基S1氨基酸序列的Tyr89，Tyr8，Gly44，Thr53和Gly80缺失，并被天然氨基酸组中选择的不同氨基酸残基取代; 还描述了能够提供和分泌所述PT突变体的Bordetella菌株及其获得方法和方法。 由它们生产的博德氏菌属菌株和PT突变体特别适用于制备有效的细胞和无细胞的抗百日咳疫苗。

    Bacterial outer memberane vesicles
    49.
    发明申请
    Bacterial outer memberane vesicles 审中-公开
    细菌外囊泡

    公开(公告)号：US20060166344A1

    公开(公告)日：2006-07-27

    申请号：US10526113

    申请日：2003-09-01

    申请人： Mariagrazia Pizza ,  Davide Serruto ,  Rino Rappuoli

    发明人： Mariagrazia Pizza ,  Davide Serruto ,  Rino Rappuoli

    IPC分类号： C12N9/00

    CPC分类号： A61K39/095 ,  A61K2039/55555 ,  C07K14/22 ,  C12N1/06 ,  C12N1/20 ,  C12N13/00

    摘要： Existing methods of meningococcal OMV preparation involve the use of detergent during disruption of the bacterial membrane. According to the invention, membrane disruption is performed substantially in the absence of detergent. The resulting OMVs which retain important bacterial immunogenic components, particularly (i) the protective NspA surface protein, (ii) protein NMB2132 and (iii) protein NMB 1870. A Typical process involves the following steps: (a) treating bacterial cells in the substantial absence of detergent; (b) centrifuging the composition from step (a) to separate the outer membrane vesicles from treated cells and cell debris, and collecting the supernatant; (c) performing a high speed centrifugation of the supernatant from step (b) and collecting the outer membrane vesicles in a pellet; (d) re-dispersing the pellet from step (c) in a buffer; (e) performing a second high speed centrifugation in accordance with step (c), collecting the outer membrane vesicles in a pellet; (f) re-dispersing the pellet from step (e) in an aqueous medium.

    摘要翻译： 脑膜炎球菌OMV制剂的现有方法涉及在细菌膜破坏期间使用洗涤剂。 根据本发明，膜破坏基本上在没有洗涤剂的情况下进行。 所产生的OMV保留了重要的细菌免疫原性成分，特别是（i）保护性NspA表面蛋白，（ii）蛋白NMB2132和（iii）蛋白NMB1870。典型的方法包括以下步骤：（a） 不含洗涤剂; （b）将来自步骤（a）的组合物离心以将外膜囊泡与经处理的细胞和细胞碎片分离，并收集上清液; （c）对来自步骤（b）的上清液进行高速离心并将颗粒中的外膜囊泡收集; （d）将来自步骤（c）的沉淀物重新分散在缓冲液中; （e）根据步骤（c）进行第二高速离心，将外膜囊泡收集在颗粒中; （f）将来自步骤（e）的沉淀物重新分散在水性介质中。